As of December 31, 2025, UNIMED achieved a turnover of 148.9 million dinars (MD), a slight increase compared to the 147.7 MD recorded at the end of December 2024.
This growth was mainly driven by the positive momentum of sales on the local market. In this regard, official sales recorded significant growth of 16%, reaching 50.5 MD compared to 43.6 MD a year earlier. Additionally, export activity showed a positive increase of 3%.
Total production, expressed in units (ampoules, vials, syringes, and bags), reached 245.8 million units as of December 31, 2025, representing however a decrease of 4% compared to the previous fiscal year.
Tangible and intangible investments made during the year 2025 amounted to 4.4 MD, primarily allocated to layout and development works.
Regarding the financial structure, long-term debt stood at 17.6 MD as of December 31, 2025, a decrease of 29% compared to the end of 2024.
Short-term debts reached 27.4 MD, comprising notably less than one-year maturities on bank loans for 7.1 MD, on leasing credits for 0.9 MD, as well as management credits for 19.4 MD, a slight increase of 2% compared to the previous fiscal year.
Finally, the company’s total workforce stood at 809 employees as of December 31, 2025.
